- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07601685
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) (EKNMERC-GCF-SL)
Expression of Mitochondria-Endoplasmic Reticulum Contact Proteins in Saliva and Gingival Crevicular Fluid in Patients With Periodontal Disease: ELISA and Calcium Analysis
This observational cross-sectional study investigates the levels of mitochondria-endoplasmic reticulum contact site (MERC) proteins in saliva and gingival crevicular fluid (GCF) of individuals with different periodontal conditions. MERCs are specialized regions where mitochondria and the endoplasmic reticulum physically connect, and they play important roles in calcium signaling, oxidative stress regulation, and cell death (apoptosis). Disruption of these contact sites has been linked to inflammatory diseases, including periodontal disease.
The study includes 48 systemically healthy, non-smoking adults divided into three groups: periodontally healthy (n=16), gingivitis (n=16), and Stage III Grade B periodontitis (n=16). Five MERC-associated proteins (VAPB, PTPIP51, IP3R, GRP75, and VDAC) are measured in GCF and saliva samples using ELISA. Additionally, caspase-3 (a marker of apoptosis), reactive oxygen species (a marker of oxidative stress), and calcium levels are measured to explore relationships between MERC proteins and key cellular processes involved in periodontal tissue destruction.
The purpose of this study is to determine whether MERC protein levels differ across periodontal conditions and to evaluate their associations with clinical periodontal parameters, oxidative stress, calcium metabolism, and apoptosis.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Mitochondria-endoplasmic reticulum contact sites (MERCs) are specialized structural domains that physically link mitochondria and the endoplasmic reticulum. These contact sites are enriched with functional proteins that coordinate calcium transfer between the two organelles, regulate lipid metabolism, modulate oxidative stress responses, and control apoptotic signaling pathways. Key MERC-associated proteins include VAPB (vesicle-associated membrane protein-associated protein B), PTPIP51 (protein tyrosine phosphatase-interacting protein 51), IP3R (inositol 1,4,5-trisphosphate receptor), GRP75 (glucose-regulated protein 75), and VDAC (voltage-dependent anion channel). The IP3R-GRP75-VDAC complex facilitates calcium transfer from the ER to mitochondria, while the VAPB-PTPIP51 complex modulates this process and influences ATP production and autophagy. Disruption of MERC homeostasis has been implicated in neurodegenerative diseases, metabolic disorders, and periodontal disease. Periodontal disease is a chronic inflammatory condition driven by microbial dental plaque, leading to destruction of periodontal tissues and alveolar bone. Previous studies demonstrated dysregulation of MERC-related gene expression (MFN1, IP3R, GRP75, PINK1, SIGMAR1) in human gingival fibroblasts exposed to Porphyromonas gingivalis and Fusobacterium nucleatum.
The present study measures the concentrations and total amounts of five MERC proteins-VAPB, PTPIP51, IP3R, GRP75, and VDAC-together with caspase-3 (an apoptosis marker), reactive oxygen species (ROS, an oxidative stress marker), and calcium levels in gingival crevicular fluid (GCF) and unstimulated whole saliva obtained from systemically healthy, non-smoking participants. Participants are classified into three groups according to the 2017 World Workshop classification: periodontally healthy (n=16), gingivitis (n=16), and Stage III Grade B periodontitis (n=16), with equal sex distribution (8 males and 8 females per group). GCF samples are collected from three single-rooted teeth per participant using standardized paper strips (Periopaper), with absorbed volume measured using a Periotron 8000. Saliva samples are collected using the passive drooling method. Biomarker levels are quantified using commercially available ELISA kits. Clinical periodontal parameters recorded include Plaque Index (PI), Gingival Index (GI), Probing Depth (PD), Bleeding on Probing (BOP%), and Clinical Attachment Level (CAL). Correlations between biomarker levels and clinical parameters are analyzed. Receiver operating characteristic (ROC) curve analysis is performed to evaluate the diagnostic potential of the biomarkers.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Malatya
-
Malatya, Malatya, Turquia (Türkiye), 44210
- Inönü University Faculty of Dentistry, Department of Periodontology
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Systemically healthy individuals aged 18-65 years
- Non-smokers or smoking cessation more than 5 years ago
- Healthy group: No history of periodontal disease, ≥20 teeth, probing depth (PD) ≤3 mm at all sites, bleeding on probing (BOP) <10%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth
- Gingivitis group: No history of periodontal disease, ≥20 teeth, PD ≤3 mm at all sites, BOP ≥30%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth
- Periodontitis group: ≥15 teeth, >30% of teeth affected by periodontal disease, PD ≥6 mm, clinical attachment loss (CAL) ≥5 mm, vertical bone loss ≥3 mm, Class II or III furcation involvement, radiographic alveolar bone loss extending to the middle third or beyond (≥33%), bone loss-to-age ratio between 0.25 and 1.00
Exclusion Criteria:
- Periodontal treatment or antibiotic use within the past 6 months
- Fewer than 20 teeth (excluding third molars)
- Presence of any systemic disease
- Current smoking or cessation within the past 5 years
- Use of immunosuppressive medication
- Alcohol consumption
- Regular medication use
- Pregnancy or lactation
- Need for antibiotic prophylaxis prior to dental procedures
- Prosthetic restorations on the teeth selected for sampling
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Periodontally Healthy
Systemically healthy, non-smoking individuals with no history of periodontal disease.
Inclusion criteria: ≥20 teeth, probing depth (PD) ≤3 mm at all sites, bleeding on probing (BOP) <10%, and radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth.
n=16 (8 females, 8 males).
|
Levels of MERC-associated proteins (VAPB, PTPIP51, IP3R, GRP75, VDAC), caspase-3, reactive oxygen species, and calcium were measured in gingival crevicular fluid and unstimulated whole saliva samples using commercially available ELISA kits.
Absorbance was read at 450 nm.
No therapeutic intervention was applied; this is an observational biomarker measurement study.
Calcium levels were measured in gingival crevicular fluid and unstimulated whole saliva samples using a commercially available ELISA kit (ELK Biotechnology, China).
Concentrations were expressed as μmol/mL and total amounts as μmol/30s.
Analytical range: 0.15-40 μmol/mL.
No therapeutic intervention was applied.
|
|
Gingivitis
Systemically healthy, non-smoking individuals with gingival inflammation but no attachment loss.
Inclusion criteria: ≥20 teeth, PD ≤3 mm at all sites, BOP ≥30%, and radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth.
n=16 (8 females, 8 males).
|
Levels of MERC-associated proteins (VAPB, PTPIP51, IP3R, GRP75, VDAC), caspase-3, reactive oxygen species, and calcium were measured in gingival crevicular fluid and unstimulated whole saliva samples using commercially available ELISA kits.
Absorbance was read at 450 nm.
No therapeutic intervention was applied; this is an observational biomarker measurement study.
Calcium levels were measured in gingival crevicular fluid and unstimulated whole saliva samples using a commercially available ELISA kit (ELK Biotechnology, China).
Concentrations were expressed as μmol/mL and total amounts as μmol/30s.
Analytical range: 0.15-40 μmol/mL.
No therapeutic intervention was applied.
|
|
Stage III Grade B Periodontitis
Systemically healthy, non-smoking individuals with Stage III Grade B periodontitis.
Inclusion criteria: ≥15 teeth, >30% of teeth affected, PD ≥6 mm, CAL ≥5 mm, vertical bone loss ≥3 mm, Class II/III furcation involvement, radiographic bone loss extending to the middle third or beyond (≥33%), and bone loss-to-age ratio between 0.25 and 1.00.
n=16 (8 females, 8 males).
|
Levels of MERC-associated proteins (VAPB, PTPIP51, IP3R, GRP75, VDAC), caspase-3, reactive oxygen species, and calcium were measured in gingival crevicular fluid and unstimulated whole saliva samples using commercially available ELISA kits.
Absorbance was read at 450 nm.
No therapeutic intervention was applied; this is an observational biomarker measurement study.
Calcium levels were measured in gingival crevicular fluid and unstimulated whole saliva samples using a commercially available ELISA kit (ELK Biotechnology, China).
Concentrations were expressed as μmol/mL and total amounts as μmol/30s.
Analytical range: 0.15-40 μmol/mL.
No therapeutic intervention was applied.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
GCF VAPB Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of VAPB in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary VAPB Levels
Prazo: At baseline (single visit)
|
Concentrations of VAPB (pg/mL) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
GCF PTPIP51 Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of PTPIP51 in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary PTPIP51 Levels
Prazo: At baseline (single visit)
|
Concentrations of PTPIP51 (ng/L) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
GCF IP3R Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of IP3R in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary IP3R Levels
Prazo: At baseline (single visit)
|
Concentrations of IP3R (ng/mL) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
GCF GRP75 Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of GRP75 in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary GRP75 Levels
Prazo: At baseline (single visit)
|
Concentrations of GRP75 (ng/mL) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
GCF VDAC Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of VDAC in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary VDAC Levels
Prazo: At baseline (single visit)
|
Concentrations of VDAC (ng/mL) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
GCF Caspase-3 Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of caspase-3 (ng/mL) in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary Caspase-3 Levels
Prazo: At baseline (single visit)
|
Concentrations of caspase-3 (ng/mL) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
GCF Reactive Oxygen Species Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of reactive oxygen species (ROS) in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary Reactive Oxygen Species Levels
Prazo: At baseline (single visit)
|
Concentrations of reactive oxygen species (ROS) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
GCF Calcium Levels
Prazo: At baseline (single visit)
|
Concentrations and total amounts of calcium (µmol/mL) in gingival crevicular fluid measured by ELISA.
|
At baseline (single visit)
|
|
Salivary Calcium Levels
Prazo: At baseline (single visit)
|
Concentrations of calcium (µmol/mL) in unstimulated whole saliva measured by ELISA.
|
At baseline (single visit)
|
|
Plaque Index
Prazo: At baseline (single visit)
|
Plaque Index (PI) recorded at sampling sites.
|
At baseline (single visit)
|
|
Gingival Index
Prazo: At baseline (single visit)
|
Gingival Index (GI) recorded at sampling sites.
|
At baseline (single visit)
|
|
Probing Depth
Prazo: At baseline (single visit)
|
Probing Depth (PD) recorded at sampling sites.
|
At baseline (single visit)
|
|
Bleeding on Probing
Prazo: At baseline (single visit)
|
Bleeding on Probing (BOP%) recorded at sampling sites.
|
At baseline (single visit)
|
|
Clinical Attachment Level
Prazo: At baseline (single visit)
|
Clinical Attachment Level (CAL) recorded at sampling sites.
|
At baseline (single visit)
|
|
Gingival Crevicular Fluid Volume
Prazo: At baseline (single visit)
|
Gingival crevicular fluid (GCF) volume measured at sampling sites.
|
At baseline (single visit)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Cüneyt A Aral, Professor, DDS, PhD, Inonu University
Publicações e links úteis
Publicações Gerais
- Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, Greenwell H, Herrera D, Kao RT, Kebschull M, Kinane DF, Kirkwood KL, Kocher T, Kornman KS, Kumar PS, Loos BG, Machtei E, Meng H, Mombelli A, Needleman I, Offenbacher S, Seymour GJ, Teles R, Tonetti MS. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018 Jun;45 Suppl 20:S162-S170. doi: 10.1111/jcpe.12946.
- Chapple ILC, Mealey BL, Van Dyke TE, Bartold PM, Dommisch H, Eickholz P, Geisinger ML, Genco RJ, Glogauer M, Goldstein M, Griffin TJ, Holmstrup P, Johnson GK, Kapila Y, Lang NP, Meyle J, Murakami S, Plemons J, Romito GA, Shapira L, Tatakis DN, Teughels W, Trombelli L, Walter C, Wimmer G, Xenoudi P, Yoshie H. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S74-S84. doi: 10.1002/JPER.17-0719.
- Lim D, Dematteis G, Tapella L, Genazzani AA, Cali T, Brini M, Verkhratsky A. Ca2+ handling at the mitochondria-ER contact sites in neurodegeneration. Cell Calcium. 2021 Sep;98:102453. doi: 10.1016/j.ceca.2021.102453. Epub 2021 Aug 5.
- Lee S, Min KT. The Interface Between ER and Mitochondria: Molecular Compositions and Functions. Mol Cells. 2018 Dec 31;41(12):1000-1007. doi: 10.14348/molcells.2018.0438. Epub 2018 Dec 12.
- Kirmizigul OA, Sabanci A, Disli F, Yildiz S, Milward MR, Aral K. Evaluation of the role of mitofusin-1 and mitofusin-2 in periodontal disease. J Periodontol. 2024 Jan;95(1):64-73. doi: 10.1002/JPER.23-0072. Epub 2023 Jul 24.
- Aral K, Milward MR, Cooper PR. Gene expression profiles of mitochondria-endoplasmic reticulum tethering in human gingival fibroblasts in response to periodontal pathogens. Arch Oral Biol. 2021 Aug;128:105173. doi: 10.1016/j.archoralbio.2021.105173. Epub 2021 May 27.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças bucais
- Doenças estomatognáticas
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Genéticas, Congênitas
- Infecções
- Doenças Neurodegenerativas
- Doenças Gengivais
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Doenças da Medula Espinhal
- Discinesias
- Doenças Cerebelares
- Ataxia Cerebelar
- Degenerações espinocerebelares
- Ataxia
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Periodontite
- Doenças Periodontais
- Ataxias espinocerebelares
- Gengivite
Outros números de identificação do estudo
- IUCTEC.2024/06
- TDH-2024-3464 (Número de outro subsídio/financiamento: Inönü University Scientific Research Projects Coordination Office)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em ELISA Biomarker Analysis
-
ORIOL BESTARDConcluídoTransplante Renal | Infecção por CMVEspanha, Bélgica
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), Singapore; Genome Institute of Singapore e outros colaboradoresRecrutamento
-
Ajay Wasan, MD, MscNational Center for Complementary and Integrative Health (NCCIH)RecrutamentoDor miofacial | Dor lombar crônica (cLBP)Estados Unidos
-
The Methodist Hospital Research InstituteAinda não está recrutandoLeucemia Mielóide Aguda (LMA) | Leucemia Mielóide Aguda (LMA)Estados Unidos